These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30675755)

  • 1. The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.
    Harari S; Caminati A; Confalonieri M; Poletti V; Vancheri C; Pesci A; Rogliani P; Luppi F; Agostini C; Rottoli P; Sanduzzi Zamparelli A; Sebastiani A; Della Porta R; Salton F; Messore B; Tomassetti S; Rosso R; Biffi A; Puxeddu E; Cerri S; Cinetto F; Refini RM; Bocchino M; Di Michele L; Specchia C; Albera C;
    Clin Respir J; 2019 Mar; 13(3):166-173. PubMed ID: 30675755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
    Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
    Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
    Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
    PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
    Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
    Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust.
    Casillo V; Cerri S; Ciervo A; Stendardo M; Manzoli L; Flacco ME; Manno M; Bocchino M; Luppi F; Boschetto P
    BMC Pulm Med; 2019 Sep; 19(1):170. PubMed ID: 31488107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival.
    Tanaka S; Miyoshi K; Higo H; Kurosaki T; Otani S; Sugimoto S; Yamane M; Kiura K; Toyooka S; Oto T
    Respir Investig; 2019 Mar; 57(2):165-171. PubMed ID: 30600175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
    Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
    J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone improves survival in IPF: results from a real-life study.
    Margaritopoulos GA; Trachalaki A; Wells AU; Vasarmidi E; Bibaki E; Papastratigakis G; Detorakis S; Tzanakis N; Antoniou KM
    BMC Pulm Med; 2018 Nov; 18(1):177. PubMed ID: 30470213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.